

Patient triggered follow up (PTFU) for prostate cancer patients post radiotherapy and radical prostatectomy

Werner Struss
MD, FEBU, FECSM



CONFLICTS OF INTEREST

- None

924 PATIENTS INCLUDED IN THIS STUDY




Table 1: clinical characteristics

Risk Stratification	Prostatectomy	Radiotherapy
Age	72 (IQR 67-76)	75 (IQR 70-80)
Presenting PSA at diagnosis	6.4 (IQR 4.0-9.5)	7.6 (IQR 3.8-14.0)
Grade group		
Low risk	42 (9%)	60 (12%)
Low tier intermediate risk	240 (55%)	193 (40%)
High tier intermediate risk	90 (21%)	111 (22%)
High risk	25 (6%)	59 (12%)
Very high risk	37 (8%)	61 (13%)
Unknown	3 (1%)	3 (1%)
Stage		
Localised (T1N0-T3N0)	396 (91%)	439 (90%)
Locally advanced (T2N1-T4N1)	41 (9%)	48 (10%)

Table 2: Treatment characteristics

Surgery	
Laparoscopic prostatectomy	151 (34%)
Open retropubic prostatectomy	82 (19%)
Robotic prostatectomy	182 (42%)
Perineal prostatectomy	22 (5%)
Radiotherapy	
Low dose rate brachytherapy	72 (15%)
High dose rate brachytherapy	58 (12%)
External beam radiotherapy	357 (73%)

RESULTS & CONCLUSION

- **437 radical prostatectomy patients**
 - Median start post Sx 13.7 months (IQR 4.9-39.0)
 - Patient triggered FU 36.6 months (IQR 19.8-55.7)
 - 31 (7%) patients recalled
 - 5 (1%) patients discharged
- **487 radiotherapy patients**
 - Median start time post RT 13.2 months (IQR 5.0-38.9)
 - Median patient triggered FU 39.8 months (IQR 21.3-51.3)
 - 43 patients recalled
 - 10 patients discharged
- 22 patients deaths (non-prostate cancer related causes)
- PTFU the overall cost reduction £63,450/a

Clinically safe

Patient accepted

Financially beneficial